

## Subject Index

### a

- ab initio* methods 31
- absolute bioavailability 198f.
- Acebutolol 154
- ADME/Tox properties 150ff., 193ff.
  - absorption 199ff.
  - distribution 202f.
  - elimination 206.
  - metabolism 203ff.
  - toxicity 207ff.
- agonist 115
- albumin 202f.
- aldose reductase 105
- algorithms, *see also* search algorithms
  - Backpropagation algorithm 226f.
  - Kohonen's algorithm 216
  - Maximim algorithm 157f.
- alignment-free descriptors 13, 106
- allosteric modulator 115
- amino acids 58
- Amiodarone 207
- ant colony optimization, ACO 248ff.
  - MHC I protein prediction 249ff.
- antagonist 115
- antibiotic 117
- aqueous solubility 195ff.
- artificial neural network, ANN 224ff.
- atom typing 70f.
- atom-pair descriptor 63ff.
  - CATS descriptor 67f.
  - similarity calculations 64
- autocorrelation 12f., 66ff.
  - ATS descriptor 66
  - GRIND descriptor 66f.
- automated compound classification 212
- automated conformer generation 29
  - force-field method 29ff.
  - knowledge-based approach 31f.

### b

- Backpropagation algorithm 226f.
- Bayes Theorem 221
- benzisoxazoles 166
- benzopyran motif 21
- beta-secretase 176
- beta-turn mimetics 62
- binary classifiers 213
- binding-site analysis 101ff.
  - automated pocket extraction 103
  - binary fingerprinting 104
  - descriptors 104ff.
  - gap sphere concept 101
  - grid-based principle 101, 126
- bioactive conformation 32f., 39
- bioavailability 198f.
- biochemical competition assay 46
- bioisosteres 211
- biophore concept 58ff.
  - 2D biophore concept 60
  - motifs 62
  - protein-protein interactions 62
- Biotin-Avidin interaction 117
- “black list”, *see* flagging list
- Bongard problem 48
- breadth-first algorithm 139f.

### c

- calorimetric techniques 45f.
- cannabinoid-1 (CB-1) receptor 186ff.
  - *de novo* ligand design 187ff.
- Carteolol 206
- CATS descriptor 67f.
- cavitation energy 196
- Cheng-Prusoff equation 46
- Ciprofloxacin 164
- Classification and Regression Tree, CART 174
- classifier development 212
- Clopidrogel 211

- combinatorial library, *see also* compound library
  - Comparative Molecular Field Analysis, CoMFA 52ff.
  - compound library 15, 107ff., 149ff., 233ff.
    - chemotype diversity 171f.
    - combinatorial library 149
    - databases 108
    - diversity 16
    - enrichment factor 155f.
    - focused library 154ff.
    - ligand-based design 107ff.
    - machine learning methods 212ff.
    - privileged library 109f., 240
    - reference compounds 109
  - computer-assisted molecular design, CAMD 87ff.
  - correlation-vector descriptor 67
  - crystal packing energy 196
  - Cyclooxygenase inhibitors 69f.
  - cytochrome P450, CYP 113f., 203ff.
    - induction 207
    - inhibition 209
    - substrates 204
- d**
- data scaling 232f.
    - autoscaling 232
    - block-scaling 232f.
    - histogram equalization 232f.
    - logistic scaling 232f.
  - databases 108
  - de novo* design 1, 124ff., *see also* receptor-based *de novo* design
    - atom-based approach 127
    - constraints 125
    - docking 127
    - fragment-based approach 127ff.
    - ligand-based design 138
    - linking approach 130f.
    - molecular dynamics simulation 134f.
    - RECAP procedure 143
    - receptor-based design 126ff.
    - scoring 135ff.
    - search strategies 139ff.
  - depth-first algorithm 139f.
  - descriptors, *see* molecular descriptors
  - dichloro-isoproterenol 116
  - dihydrofolate reductase, DHFR 7
  - dihydroorotate dehydrogenase, DHODH 133
  - dissociation constant,  $K_d$  37
  - diversity measurement 160ff.
  - DNA gyrase 163f.
  - docking methods 74ff.
    - *de novo* design 127
    - flexible fit 83
    - homology model 114
  - dopamin D<sub>3</sub> receptor 244ff.
  - dopaminergic system 244
  - drug absorption 199ff.
    - simulation models 201
  - drug administration 198f.
  - drug attributes 15
  - drug development 150ff.
  - drug elimination 206
  - drug metabolism 203ff.
    - *in silico* methods 204f.
  - drug targets 89ff., 109ff.
    - family-specific compound libraries 109f.
    - integral membrane proteins 123f.
    - target classes 90ff.
  - drug-drug interactions 113
  - drug-likeness concept 14ff.
    - criteria 15
    - neural network prediction 233f.
  - druglike substituents 19
- e**
- enrichment factor, *ef* 155f.
  - enzyme-substrate complex, *see* ligand-protein interaction
  - evolutionary algorithm, EA 140ff.
    - strategy parameter 141
- f**
- feature extraction 212ff.
    - principal component analysis, PCA 212ff.
    - self-organizing map, SOM 212, 216ff.
  - Feature Point Pharmacophores, FEPOPS 65f.
  - 2D fingerprint 21f.
  - flagging list 21
  - flexible fit, *see* induced fit
  - focused library 154ff.
  - force-field method 29ff.
  - Free Energy Perturbation, FEP 41ff., 137
    - thermodynamic cycle 42
  - Free-Wilson analysis 49ff.
  - frequent hitter 165f.
  - fuzzy pharmacophore model 70ff.
- g**
- G-protein coupled receptor, GPCR 21, 90, 114ff., 186ff.
    - cannabinoid receptor, CB-1 187ff.
    - classes 188f.
    - GPCR-focused combinatorial library 60f.

- ligand activity 115
- metabotropic glutamate receptor, mGluR 242ff.
- promiscuous binding 166
- Rhodopsin 114
- gap sphere concept 101
- gastrointestinal tract 198ff.
- Geldanamycin 44
- genetic algorithm 141
- Genistein 166
- Ghose-Crippen fingerprint 219f.
- Gibbs energy 36
- Gleevec 82
- grid-based principle 101, 126
  - GRID software 126
- Grid-Independent Descriptors, GRIND 66

**h**

- Hansch analysis 51
- hard-sphere pharmacophores 69f.
- hepatic excretion 206
- hERG K<sup>+</sup>-channel 208
- high-throughput screening, HTS 15, 88, 108, 151ff.
  - SHAPES approach 152
  - *ultra*HTS 152
- Hirudin 117f.
- hit-to-lead procedure 153
- homology-based modeling 114
- hydrogen bond 54ff.
  - interaction spheres 56
- hydrogen-bridge 55
- hydrophobic effect 39f.
- hydrophobicity 194
- hydroxamate 132

**i**

- IC-values 46
- Imatanib 81
- induced fit effect 33ff., 77ff., 105
  - examples 80ff.
  - modeling 83
- inductive learning 49
- inhibition constant,  $K_i$  37, 46
- integral membrane protein 123f.
- interaction site calculation 126
- inverse agonist 115
- inverse Boltzmann method 32
- ion channel modulators 178
  - hERG K<sup>+</sup>-channel 208
  - Kv1.5 178ff.
- virtual screening methods 179ff.
- isoproterenol 116
- Isothermal Titration Calorimetry, ITC 45

**k**

- key interaction sites 126f.
- kinase inhibitors 81f.
  - Gleevec 82
- kinesin-like spindle protein 80
- knowledge-based potential 31f.
- Kullback-Leibler divergence 161

**l**

- lead structure 149ff.
  - optimization 153f.
  - series 154
- ligand efficiency 153f.
- Ligand-Based Quantification of Interaction Distribution, LIQUID 70ff.
- ligand-based scoring 138
- ligand-protein interaction, *see also* ligand-receptor interaction
  - aromatic interactions 57
  - binding pockets 100f.
  - binding-site analysis 101ff.
  - biophore concept 58ff.
  - induced fit effect 77f.
  - pharmacophore 59ff.
  - thermodynamics 35ff.
  - transition state analog 119ff.
  - water contribution 38ff.
- ligand-receptor complex 35
  - Avidin-Biotin complex 45, 117
  - cation- $\pi$  complex 57
  - flexibility 44f.
  - formation 37
    - Gleevec-Abl interaction 82
    - ligand-binding modes 112
    - PPAR-Rosiglitazone complex 82
    - sHE-inhibitor complex 79
    - thrombin-hirudin complex 117
- ligand-receptor interaction 35ff., 54ff., 87ff.
  - conformation 29, 39ff.
  - dissociation constant 46
  - docking tools 74ff.
  - enthalpic contribution 45ff.
  - entropic contribution 38ff.
  - equilibrium state 37
  - hydrogen bonds 54ff.
  - hydrophobic effect 39f.
  - ionic interactions 57
  - molecular partition function 40ff.
  - pharmacophore 59ff.
  - QSAR modeling 47ff.
  - shape complementarity 7
  - thermodynamics 35ff.
  - types 54
- linkers 17

- Lipinski's rule-of-five 14f., 109, 197
  - lipophilicity 193ff.
    - distribution coefficient *D* 194
    - *in silico* methods 195
    - partition coefficient *P* 194
  - 5-lipoxygenase, 5-LO 183
    - inhibitors 184
    - virtual screening 184ff.
  - local feature density, LFD 71f.
- m**
- machine learning methods 212ff.
    - ant colony optimization, ACO 248ff.
    - artificial neural network, ANN 225ff.
    - case studies 242ff.
    - compound library design 233ff.
    - naïve Bayes classifier 221ff.
    - Principal Component Analysis, PCA 212ff.
    - self-organizing map, SOM 212, 216ff.
    - Support Vector Machine, SVM 227ff.
  - major histocompatibility complex (MHC) I 249f.
  - matrix metalloproteinase (MMP) inhibitors 132
  - matrix representation 8ff.
    - pharmacophore matrix 67
  - Matthew correlation coefficient 250f.
  - Maxxim algorithm 157f.
  - Memantine 170
  - membrane 193, 199
    - paracellular transport 199f.
    - transcellular transport 199f.
  - metabotropic glutamate receptor, mGluR 242
    - modulators 242ff.
  - Methotrexate 7
  - Metropolis criterion 140
  - Metroprolol 154
  - mitochondrial NADH/ubiquinone oxidoreductase inhibitor 60
  - molecular descriptors 12ff., 66ff., 104ff.
    - ATS descriptor 66
    - CATS descriptor 67f.
    - correlation-vector descriptors 67
    - FeatureTree descriptor 148
    - Grid-Independent Descriptor, GRIND 66
    - pharmacophore-based pocket descriptors 106f.
    - shape descriptor 104ff.
    - VolSurf descriptors 202f.
  - molecular docking, *see* docking methods
  - molecular dynamics
    - bond angles 5f.
    - bond lengths 5f.
    - physical treatment 1
    - simulation 134f.
  - molecular framework 17
  - molecular graphs 8ff.
    - alignment-free descriptor 13
    - graph invariant 11ff.
    - hydrogen-depleted graph 67
    - SMILES notation 23
    - topological distance matrix 67
  - Molecular Mechanics – Poisson Boltzmann Surface Area, MM-PBSA 43
  - molecular models
    - modeling packages 5
    - simplifications 2
  - molecular partition function 40f.
  - molecular representations 2ff., 60
    - atom typing 28
    - automated conformer generation 29
    - bitstring 21
    - molecular graph 8ff.
    - numerical vector 13, 60
    - shape complementarity 7
    - SMILES notation 23ff.
    - Structure Data Format, SDF 10
    - surfaces 3
    - SYBYL line notation 28
  - molecular shape 7
  - molecular surface 3ff.
    - Connolly algorithm 4
    - isosurface 167
    - shape matching 167ff.
    - Solvent Accessible Surface, SAS 3
    - surface patches 168
  - molecule segmentation 16
  - Monastrol 80
  - monoamine oxidase, MAO 112
  - Monte Carlo algorithm 140
  - multilayer Perceptrons 225
  - multiobjective design 135ff.
  - Multiple Copy Simultaneous Search, MCSS 127
- n**
- naïve Bayes classifier 221ff.
  - natural product 116ff.
    - antibiotic agent 117
    - Pathenolide 118f.
    - scaffolds 16
  - negative design 125, 162ff.
  - New Chemical Entity, NCE 16, 87
  - NMR Analysis of Molecular Flexibility In Solution, NAMFIS 44
  - Novobiocin 164
  - nuclear magnetic resonance, NMR 152

**o**

orphan target 178  
 outliers 77ff.

**p**

Parallel Artificial Membrane Permeability Assay, PAMPA 200  
 Pareto optimization 136  
 Pargyline 112  
 Particle Swarm optimization, PSO 253  
 Parthenolide 118f.  
 peroxisome proliferator-activated receptor, PPAR 82  
 Pfizer rules, *see* Lipinski's rule-of-five  
 pharmacokinetics 193ff.  
 – clearance 198  
 – elimination rate 198  
 – half-life 198  
 – volume of distribution 197f.  
 pharmacophore concept 59ff.  
 – correlation vector approach 66ff.  
 – 3D-alignment 60  
 – fuzzy pharmacophores 70ff.  
 – potential pharmacophoric points, PPPs 60, 63ff.  
 pharmacophore descriptors 63ff.  
 pharmacophore matrix 67  
 pharmacophore models 69ff., 138  
 – generation 70ff.  
 pharmacophore road map 238ff.  
 – SOM approach 239  
 pharmacophore-based pocket descriptors 106f.  
 Phosphoramidon 121  
 physicochemistry 193ff.  
 Pironavir 211  
 “Pocketome” 106  
 positive design 124, 162ff.  
 potential pharmacophoric points, PPPs 63ff., 70ff.  
 – atom-pair descriptors 63  
 – categories 64f.  
 – clustering 71ff.  
 – LIQUID approach 70ff.  
 Principal Component Analysis, PCA 72, 212ff.  
 – principal components, PC 212  
 privileged motif 20ff.  
 – target-family preferring motif 21  
 prodrug 210f.  
 – double prodrug 210  
 Projection to Latent Structures, PLS 213ff.  
 promiscuous binder 166  
 protein folds 100

protein kinase C, PKC 113  
 protein-ligand interaction, *see* ligand-protein interaction  
 protein-protein interaction 62  
 – induced fit 83  
 purine nucleoside phosphorylase, PNP 119f.

**q**

Quantitative Structure-Activity Relationship, QSAR 47ff., 77ff.  
 – alternative ligand binding mode 77ff.  
 – Free-Wilson analysis 49ff.  
 – general rules 47  
 – Hansch analysis 51, 79  
 – inductive learning 48f.  
 – outliers 77ff.  
 quantum mechanical calculation 2  
 3D-QSAR 52ff.  
 – Root Mean Square Deviation, RMSD 52

**r**

RECAP fragmentation 143  
 Receiver Operator Characteristic (ROC) analysis 251f.  
 – ROC curve 156, 251f.  
 receptor-based *de novo* design 126ff.  
 – CAVEAT 131  
 – HSITE 126  
 – linking approach 130  
 – LUDI 129ff.  
 – place-and-grow procedure 128f.  
 receptor-based scoring 137f.  
 – BOMB 137  
 receptor-ligand interaction, *see* ligand-receptor interaction  
 reference compound 107ff.  
 Rhodopsin 114  
 ring systems 16  
 Root Mean Square Deviation, RMSD 52  
 Rosiglitazone 82  
 “Rule of 5”, *see* Lipinski's rule-of-five

**s**

scaffold 16ff., 171  
 – examples 19  
 – molecular equivalence index, *meqi* 171  
 – privileged motifs 21  
 – reduced molecular scaffold 17, 171  
 scaffold diversity 171f.  
 – NC50C 172  
 scaffold-hopping 18, 64, 170ff.  
 – automated docking 175ff.  
 – examples 172ff.

- identification 170f.
  - molecular shape 174f.
  - Schrödinger equation 1
  - approximations 2
  - scoring functions 76, 135ff.
  - fitness function 140
  - knowledge-based scoring 137
  - ligand-based scoring 138
  - receptor-based scoring 137f.
  - search algorithms 139ff., *see also* algorithms
    - breadth-first strategy 139f.
    - depth-first searching 139f.
    - evolutionary algorithm 140ff.
    - Monte Carlo algorithm 140
  - seed structure, *see* reference compound
  - self-organizing map, SOM 212, 216ff., 238ff.
    - algorithm 221
    - pharmacophore road map 238ff.
  - Shannon entropy 160ff.
  - shape descriptor 104ff.
  - shape matching 167ff.
  - side chains 17, 19
  - similarity principle 20ff., 111f.
    - similarity searching 21
    - Tanimoto coefficient 21
  - Simplified Molecular Input Line Entry System, SMILES 23ff.
    - Reaction SMILES 25
    - SMARTS expression 28
    - string concatenation 26f.
  - Simulated Annealing 140
  - SMILES, *see* Simplified Molecular Input Line Entry System
  - SMILES Arbitrary Target Specification, SMARTS 28
    - recursive SMARTS 28
  - soluble epoxide hydrolase, sEH 78ff.
  - solvation energy 196
  - spirodiketopiperazine 62
  - spiropiperidine motif 21
  - Src kinase 40
  - string representations 23
    - SMILES notation 23ff.
    - string concatenation 26
  - Structure Data Format, SDF 10
  - structure normalization 11
  - structure sampling 128f.
  - structure-activity relationship, SAR 1, 47ff.
    - local SAR 154
    - steep SAR 47
  - structure-property relationship, SPR 14
  - substructure elements 21
  - Support Vector Machine, SVM 227ff.
    - extensions 231f.
    - Karosh-Kuhn-Tucker conditions 231
  - surface properties 3
  - SYBYL Line Notation, SLN 28
- t**
- Tacrolimus 130f.
  - Tanimoto coefficient 21f.
  - tetrahydrocannabinol, THC 187
  - Thermodynamic Integration, TI 41
  - thermolysin 121ff.
  - thrombin 117f., 129
    - inhibitor design 129f.
  - toxicity 207ff.
    - *in silico* prediction 207
    - metabolism-induced 207
    - pharmacophore-induced 207ff.
    - structure-related 207
  - transition state analogs 119ff.
    - design 121ff.
    - integral membrane proteins 123f.
- u**
- unsupervised learning 212ff.
- v**
- “virtual ligand” concept 106f.
  - virtual screening 32, 149ff.
    - “bioactive” conformation 32f.
    - case studies 178ff.
    - cell-based approach 158ff.
    - compound sources 108
    - diversity measurement 160ff.
    - enrichment factor 155f.
    - frequent hitters 165f.
    - maximum diversity 157
    - methods 156ff.
    - promiscuous binders 166
    - receiver operating characteristic, ROC 156
    - scaffold-hopping 172ff.
    - shape matching 167ff.
    - substructure searching 21
  - virtual screening cascade 162f.
- w**
- Warfarin 204f.
  - water-protein interactions 44f.
  - World Drug Index, WDI 19, 108
- x**
- Ximelagatran 210